[go: up one dir, main page]

NO940219D0 - Rekombinante antistoffer for human terapi - Google Patents

Rekombinante antistoffer for human terapi

Info

Publication number
NO940219D0
NO940219D0 NO940219A NO940219A NO940219D0 NO 940219 D0 NO940219 D0 NO 940219D0 NO 940219 A NO940219 A NO 940219A NO 940219 A NO940219 A NO 940219A NO 940219 D0 NO940219 D0 NO 940219D0
Authority
NO
Norway
Prior art keywords
recombinant antibodies
human therapy
therapy
human
recombinant
Prior art date
Application number
NO940219A
Other languages
English (en)
Other versions
NO940219L (no
NO318097B1 (no
Inventor
Roland A Newman
Nabil Hanna
Ronald W Raab
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27112830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO940219(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of NO940219D0 publication Critical patent/NO940219D0/no
Publication of NO940219L publication Critical patent/NO940219L/no
Publication of NO318097B1 publication Critical patent/NO318097B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19940219A 1991-07-25 1994-01-21 Kimaert antistoff, farmasoytisk preparat, rekombinant nukleinsyre samt fremgangsmate for fremstilling av kimaert antistoff. NO318097B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73506491A 1991-07-25 1991-07-25
US85628192A 1992-03-23 1992-03-23
PCT/US1992/006194 WO1993002108A1 (en) 1991-07-25 1992-07-24 Recombinant antibodies for human therapy

Publications (3)

Publication Number Publication Date
NO940219D0 true NO940219D0 (no) 1994-01-21
NO940219L NO940219L (no) 1994-03-25
NO318097B1 NO318097B1 (no) 2005-01-31

Family

ID=27112830

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19940219A NO318097B1 (no) 1991-07-25 1994-01-21 Kimaert antistoff, farmasoytisk preparat, rekombinant nukleinsyre samt fremgangsmate for fremstilling av kimaert antistoff.

Country Status (24)

Country Link
EP (3) EP1266965B1 (no)
JP (1) JP3048640B2 (no)
KR (1) KR0137806B1 (no)
AP (1) AP307A (no)
AT (2) ATE237638T1 (no)
AU (1) AU673499B2 (no)
BG (1) BG62656B1 (no)
BR (1) BR9206313A (no)
CA (1) CA2114015C (no)
CZ (1) CZ289472B6 (no)
DE (2) DE69233011T2 (no)
DK (2) DK0605442T3 (no)
ES (2) ES2265005T3 (no)
FI (1) FI117703B (no)
HU (2) HUT70272A (no)
IL (1) IL102640A0 (no)
MY (1) MY121185A (no)
NO (1) NO318097B1 (no)
NZ (1) NZ243706A (no)
OA (1) OA09879A (no)
PT (1) PT100735B (no)
RO (1) RO116404B1 (no)
SK (2) SK285046B6 (no)
WO (1) WO1993002108A1 (no)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU640400B2 (en) 1989-08-07 1993-08-26 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
EP0523949B1 (en) * 1991-07-15 2003-06-25 The Wellcome Foundation Limited Production of antibodies
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
DE69405102T2 (de) 1993-06-03 1998-01-15 Therapeutic Antibodies, Inc., Nashville, Tenn. Antikoerperfragmente in therapie
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
ES2151054T3 (es) * 1994-04-26 2000-12-16 Kanebo Ltd Farmaco para el tratamiento de la artritis reumatoide.
DK0788513T3 (da) * 1994-10-25 2001-04-02 Glaxo Group Ltd Anvendelse af bindingsmidler for CD23 i behandlingen af atoimmune sygdomme
CZ172497A3 (en) * 1994-12-07 1997-10-15 Hoffmann La Roche Fragments of monoclonal substance exhibiting immunosuppressor activity
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6893636B2 (en) 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
WO1999055369A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
GB9809839D0 (en) * 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EP1112084B2 (en) 1998-08-11 2012-04-25 Biogen Idec Inc. Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
EP1131093A4 (en) 1998-11-09 2002-05-02 Idec Pharma Corp TREATMENT OF HEMATOLOGICAL VILTIES ASSOCIATED WITH CIRCULATING TUMOR CELLS USING CHIMERIC ANTI-CD20 ANTIBODIES
CA2944644C (en) 1999-05-07 2017-08-22 Genentech, Inc. Use of rituximab to treat pemphigus
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
AU7161401A (en) * 2000-07-03 2002-01-14 Gala Design Inc Host cells containing multiple integrating vectors
US6852510B2 (en) 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
KR100545945B1 (ko) * 2000-07-03 2006-01-25 갈라 디자인, 인크. 발현 벡터
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
EP1241249A1 (en) * 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
US20050101012A1 (en) 2001-03-12 2005-05-12 Gerold Schuler CD4+CD25+ regulatory T cells from human blood
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7384738B2 (en) 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
US8222033B2 (en) 2002-08-12 2012-07-17 Argos Therapeutics, Inc. CD4+CD25− T cells and Tr1-like regulatory T cells
EP1558648B1 (en) 2002-10-17 2012-01-11 Genmab A/S Human monoclonal antibodies against cd20
US20070212301A1 (en) * 2003-11-07 2007-09-13 Amgen, Inc. Monkey Immunoglobulin Sequences
ES2393674T3 (es) 2003-11-14 2012-12-27 Brigham And Women's Hospital, Inc. Métodos para modular la inmunidad
AU2005229457B2 (en) 2004-03-30 2010-11-25 Glaxo Group Limited Immunoglobulins
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
US8962278B2 (en) * 2005-08-03 2015-02-24 Ibio Inc. Compositions and methods for production of immunoglobulins
ZA200802247B (en) * 2005-08-15 2009-08-26 Arana Therapeutics Ltd Chimeric antibodies with new world primate regions
AU2006281980A1 (en) * 2005-08-15 2007-02-22 Cephalon Australia Pty Ltd Engineered antibodies with new world primate framework regions
CA2634080A1 (en) * 2005-12-20 2007-06-28 Arana Therapeutics Limited Anti-inflammatory dab
WO2007087673A1 (en) 2006-02-01 2007-08-09 Arana Therapeutics Limited Domain antibody construct
CA2661446C (en) 2006-08-11 2017-11-21 Csl Limited Treatment of pulmonary disease conditions
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
EP2530090A3 (en) 2006-10-19 2013-01-23 CSL Limited Anti-IL-13R alpha 1 antibodies and their uses thereof
EP2829551B1 (en) 2006-10-19 2017-12-13 CSL Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
TW200902544A (en) 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
AR067584A1 (es) 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
LT2646470T (lt) 2010-11-30 2017-06-12 F. Hoffmann-La Roche Ag Mažo giminingumo antitransferino receptorių antikūnai ir jų panaudojimas pernešti gydomąjį vienos grandinės antikūną (scfv) per hematoencefalinį barjerą
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
JP2015500775A (ja) * 2011-10-31 2015-01-08 エムベラ ゲゼルシャフト ミット ベシュレンクター ハフトゥング 片手操作可能なパッケージ
JP2018528763A (ja) 2015-07-31 2018-10-04 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムの除去のためのペプチドおよび抗体
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
AU2018206560B2 (en) 2017-01-04 2025-01-30 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
KR20190113858A (ko) 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
JP2020506947A (ja) 2017-02-07 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性強直性脊椎炎を治療するための抗ｔｎｆ抗体、組成物、及び方法
JP7596069B2 (ja) 2017-03-15 2024-12-09 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法
JP7541513B2 (ja) 2018-10-05 2024-08-28 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 細菌バイオフィルムの酵素的破壊のための組成物および方法
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CA3145385A1 (en) 2019-07-08 2021-01-14 Steven D. Goodman Antibody compositions for disrupting biofilms
EP4161573A1 (en) 2020-06-04 2023-04-12 BioInvent International AB Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
IL305469A (en) 2021-03-09 2023-10-01 Bioinvent Int Ab Novel combinations of antibodies and uses thereof
WO2023161448A1 (en) 2022-02-24 2023-08-31 Abnomx Bv Human-like target-binding proteins
TW202336033A (zh) 2022-03-07 2023-09-16 瑞典商生物創新國際有限公司 抗體之新穎組合及用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0523949B1 (en) * 1991-07-15 2003-06-25 The Wellcome Foundation Limited Production of antibodies

Also Published As

Publication number Publication date
CZ289472B6 (cs) 2002-01-16
ATE327331T1 (de) 2006-06-15
BR9206313A (pt) 1995-04-11
PT100735B (pt) 1999-07-30
JPH06509708A (ja) 1994-11-02
DE69233628T2 (de) 2007-04-26
AP307A (en) 1994-01-31
HUT70272A (en) 1995-09-28
AU673499B2 (en) 1996-11-14
PT100735A (pt) 1993-10-29
FI940336L (fi) 1994-03-10
IL102640A0 (en) 1993-01-14
KR0137806B1 (ko) 1998-04-30
EP1266965B1 (en) 2006-05-24
OA09879A (en) 1994-09-15
NO940219L (no) 1994-03-25
JP3048640B2 (ja) 2000-06-05
ES2265005T3 (es) 2007-02-01
ATE237638T1 (de) 2003-05-15
DK0605442T3 (da) 2003-08-04
SK285960B6 (sk) 2007-12-06
EP1266965A2 (en) 2002-12-18
BG98411A (bg) 1995-02-28
CA2114015A1 (en) 1993-02-04
EP1715045A2 (en) 2006-10-25
EP1715045A3 (en) 2006-12-13
BG62656B1 (bg) 2000-04-28
HU211881A9 (en) 1995-12-28
EP0605442A1 (en) 1994-07-13
EP1266965A3 (en) 2003-01-02
AU2425592A (en) 1993-02-23
FI117703B (fi) 2007-01-31
NZ243706A (en) 1994-08-26
MY121185A (en) 2006-01-28
NO318097B1 (no) 2005-01-31
DE69233628D1 (de) 2006-06-29
RO116404B1 (ro) 2001-01-30
DK1266965T3 (da) 2006-09-25
HU9400201D0 (en) 1994-05-30
WO1993002108A1 (en) 1993-02-04
EP0605442B1 (en) 2003-04-16
FI940336A0 (fi) 1994-01-24
DE69233011T2 (de) 2003-11-06
SK285046B6 (sk) 2006-05-04
ES2196002T3 (es) 2003-12-16
AP9200413A0 (en) 1992-07-31
DE69233011D1 (de) 2003-05-22
EP0605442A4 (en) 1995-07-12
CA2114015C (en) 2002-12-10
SK8894A3 (en) 1994-09-07
CZ14994A3 (en) 1994-07-13

Similar Documents

Publication Publication Date Title
FI940336L (fi) Yhdistelmävasta-aineita ihmisterapiaan
FI934964L (fi) Teraupetiskt aemne
FI923379L (fi) Terapeutiska amider
NO980915L (no) Rekombinante anti-CD4-antistoff egnet for human terapi
FI935878L (fi) Porfycenfoereningar foer fotodynamisk terapi
FI935175A0 (fi) Tyrosinkinas- HER4-humanreceptor
FI955798L (fi) Terapeuttiset vasta-ainefrangmentit
NO924395L (no) Rekombinante menneske-faktor viii derivater
DK0507513T3 (da) Terapeutisk anordning
FI924744L (fi) Terapeutiska aemnen
FI923759L (fi) Terapeutiska bensazapinfoereningar
FI930674A0 (fi) Terapeutiska aemnen
FI923311L (fi) Proteiner
FI934588L (fi) Insulinlik vaextfaktor bindande protein haerstammande fraon maenniskoben
BG96715A (bg) Терапевтични вещества
FI931071A0 (fi) Terapeutiska aemnen
FI920701L (fi) Anordning foer terapeutisk tryckbehandling
DK85290D0 (da) Terapeutisk virksomme forbindelser
ZA925615B (en) Recombinant antibodies for human therapy
DK149591D0 (da) Proteinpraeparat
IT9001216A0 (it) Sedia terapeutica
DK147891D0 (da) Proteinpraeparat
KR930006241U (ko) 환자용 벼개
DE69326548D1 (de) Therapeutische kombinationen
DK111891D0 (da) Polypeptid

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees